TRACON Pharmaceuticals (TCON) Earning Somewhat Positive Media Coverage, Analysis Finds

Headlines about TRACON Pharmaceuticals (NASDAQ:TCON) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.0188338392687 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the headlines that may have impacted Accern’s rankings:

Separately, Zacks Investment Research downgraded TRACON Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a research note on Friday, January 5th.

Shares of TRACON Pharmaceuticals (NASDAQ TCON) traded up $0.05 during midday trading on Friday, reaching $3.05. The company’s stock had a trading volume of 243,100 shares, compared to its average volume of 218,925. TRACON Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $5.64. The company has a current ratio of 3.80, a quick ratio of 3.80 and a debt-to-equity ratio of 0.24. The company has a market cap of $51.64 and a P/E ratio of -2.50.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.32. TRACON Pharmaceuticals had a negative return on equity of 83.43% and a negative net margin of 201.21%. The business had revenue of $7.50 million during the quarter, compared to the consensus estimate of $7.60 million. equities research analysts predict that TRACON Pharmaceuticals will post -1.21 EPS for the current fiscal year.

WARNING: This report was published by Ticker Report and is owned by of Ticker Report. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3146090/tracon-pharmaceuticals-tcon-earning-somewhat-positive-media-coverage-analysis-finds.html.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Insider Buying and Selling by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.